In a meta-analysis of 8 RCTs, FGF-21 analogs were shown to reduce NAFLD activity score (NAS) (without worsening of fibrosis) and fibrosis stage (without worsening of MASH) [63]. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.